XOMA (US) LLC
2910 Seventh Street
Berkeley
California
94710
United States
Tel: 510-204-7200 or 800-BIO-XOMA<br>
Fax: 510-644-0539
Website: http://www.xoma.com/
324 articles about XOMA (US) LLC
-
The company burned through $1.2B and never brought a drug to market in its 37 years.
-
XOMA Strengthens Leadership Team With Appointments of Chief Business Officer and General Counsel
1/8/2018
Dr. Datta and Mr. Hart will report to XOMA’s Chief Executive Officer, Jim Neal.
-
LakePharma Announces Antibody Collaboration & License Agreement With XOMA
10/4/2017
-
XOMA Earns $3 Million Milestone Payment From Its License Agreement With Nanotherapeutics
9/11/2017
-
Novartis AG Pays $31 Million+ for XOMA 's Failed Phase III Drug
8/25/2017
-
XOMA Reports Second Quarter 2017 Financial Results
8/9/2017
-
XOMA Earns $10 Million Milestone Payment As Another Of Its Licensed Assets Advances Into Clinical Development
5/18/2017
-
XOMA Reports First Quarter 2017 Financial Results
5/10/2017
-
XOMA Announces Positive Results From Its Phase II Proof-Of-Concept Study Of Prolactin Inhibition
4/24/2017
-
XOMA To Present At The Jefferies Global Healthcare Conference
6/3/2016
-
Embattled Bay Area XOMA Terminates Gevokizumab Trials
3/14/2016
-
XOMA To Present At The Cowen and Company Health Care Conference
3/3/2016
-
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition
1/4/2016
-
Novo Nordisk A/S Breathes New Life into XOMA with $295 Million Diabetes Pact
12/2/2015
-
XOMA To Present At Two Upcoming Investor Conferences
11/13/2015
-
Struggling XOMA Sells Biologics Manufacturing Facilities to Agenus, Divests Biodefense Program to Nanotherapeutics
11/6/2015
-
XOMA To Announce Third Quarter 2015 Financial Results And Host Webcast On November 5
10/30/2015
-
XOMA Initiates Proof-Of-Concept Study For XOMA 358 In Patients With Congenital Hyperinsulinism
10/26/2015
-
Novartis AG Doubles Down on Immuno-Oncology, Acquires Admune and Inks Deals With XOMA and Palobiofarma
10/22/2015
-
Troubled XOMA Nails Immuno-Oncology Pact Worth $530 Million+ With Novartis AG
10/2/2015